GHRS GH Research PLC
USHealthcareAs of 2026-10-08
Why GHRS matters now
GH Research PLC (GHRS) is a US stock in Healthcare. The latest InvestLog snapshot shows $20.45 with -2.90% on the session and $1.40B in market capitalization; recent performance reads 1-month +1.37% and YTD +75.12%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-19.0M, and EPS of $-0.31. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.1%.
The latest indexable market news headline is "GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of “Moderate Buy” from Analysts" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $39.00; recent insider activity includes Moore Duncan filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.24
P/S
0.00
EV/EBITDA
-22.96
DCF Value
$3.99
FCF Yield
-3.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-19.8%
ROA
-20.5%
ROIC
-25.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-19.0M | $-0.31 |
| Q4 2025 | $0.00 | $-14.1M | $-0.23 |
| FY 2025 | $0.00 | $-48.3M | $-0.79 |
| Q3 2025 | $0.00 | $-14.0M | $-0.23 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$40.57
Target (Median)
$39.00
Target Range
$32.00 - $65.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IE
Exchange
—
Beta
1.31
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.